Abstract

Generation of excess quantities of reactive oxygen species (ROS) caused by mitochondrial dysfunction facilitates rapid growth of pancreatic cancer cells. Elevated ROS levels in cancer cells cause an anti-apoptotic effect by activating survival signaling pathways, such as NF-κB and its target gene expression. Lycopene, a carotenoid found in tomatoes and a potent antioxidant, displays a protective effect against pancreatic cancer. The present study was designed to determine if lycopene induces apoptosis of pancreatic cancer PANC-1 cells by decreasing intracellular and mitochondrial ROS levels, and consequently suppressing NF-κB activation and expression of NF-κB target genes including cIAP1, cIAP2, and survivin. The results show that the lycopene decreased intracellular and mitochondrial ROS levels, mitochondrial function (determined by the mitochondrial membrane potential and oxygen consumption rate), NF-κB activity, and expression of NF-κB-dependent survival genes in PANC-1 cells. Lycopene reduced cell viability with increases in active caspase-3 and the Bax to Bcl-2 ratio in PANC-1 cells. These findings suggest that supplementation of lycopene could potentially reduce the incidence of pancreatic cancer.

Highlights

  • Pancreatic cancer is one of the leading causes of cancer deaths in the western world [1,2].The likelihood of surviving this disease is extremely low worldwide as indicated by the 5-year survival rate of about 6% [3]

  • Treated with lycopene induced decrease in cell viability is a consequence of an apoptotic effect, caspase-3 activation was dose-dependent manner compared to that of untreated cells

  • We found that lycopene induced apoptosis of pancreatic cancer PANC-1

Read more

Summary

Introduction

Pancreatic cancer is one of the leading causes of cancer deaths in the western world [1,2].The likelihood of surviving this disease is extremely low worldwide as indicated by the 5-year survival rate of about 6% (ranges from 2% to 9%) [3]. In Korea, the 5-year survival rate of the pancreatic cancer was 8.8% in 2012 [4]. The ability of cells to evade apoptosis, a hallmark of human cancers, could be the reason for the strong resistance of pancreatic cancer to currently available treatments [5]. The currently available drugs in the market used for the treatment of pancreatic cancer are gemcitabine (20 ,20 -difluorodeoxycytidine, GEM) and 5-fluorouracil (5-FU) [6,7]. These drugs exert their anticancer effects through the inhibition of DNA synthesis. Lee [9] recently reported that combination chemotherapy with 5-FU plus

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call